Larimar Therapeutics to Participate in SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines Event
LARIMAR Therapeutics, Inc. (Nasdaq: LRMR) announced participation in 1x1 investor meetings at the SVB Leerink CybeRx Series event focused on neuromuscular and rare diseases, scheduled for September 22-23, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
LARIMAR Therapeutics, Inc. (Nasdaq: LRMR) announced participation in 1x1 investor meetings at the SVB Leerink CybeRx Series event focused on neuromuscular and rare diseases, scheduled for September 22-23, 2021. Larimar is a clinical-stage biotech company dedicated to developing treatments for complex rare diseases, with its lead compound, CTI-1601, undergoing Phase 1 clinical trials as a potential treatment for Friedreich's ataxia. The company aims to leverage its innovative intracellular delivery platform for future therapies targeting additional rare diseases.
Details
News Market Reaction – LRMR
The recorded move for LRMR in the trading session of this news was -7.48%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BALA CYNWYD, Pa., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in 1x1 investor meetings at the SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines 1x1 Event. The event is taking place virtually September 22-23, 2021.
About Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program in the U.S. as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
(212) 915-2569
Company Contact:
Michael Celano
Chief Financial Officer
mcelano@larimartx.com
(484) 414-2715
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.